A novel approach for transforming breast cancer stem cells into endothelial cells

Mao,Qi-Qi; Ji,Xiao-Chun; Zhang,Jia-Nan; Teng,Wei-Feng; Zhou,Shao-Cheng

doi:10.3892/etm.2023.12362

A novel approach for transforming breast cancer stem cells into endothelial cells

Authors:
- Qi-Qi Mao
- Xiao-Chun Ji
- Jia-Nan Zhang
- Wei-Feng Teng
- Shao-Cheng Zhou
View Affiliations

Affiliations: Department of Thyroid and Breast Surgery, Ningbo Medical Center, Lihuili Hospital, Ningbo, Zheijiang 315040, P.R. China
Published online on: December 21, 2023 https://doi.org/10.3892/etm.2023.12362
Article Number: 74
Copyright: © Mao et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Tumor vascular endothelial cells play a pivotal in the tumor microenvironment, influencing the proliferation, invasion, and metastasis of tumor progression. The present study investigated a novel method for inducing the transformation of breast cancer stem cells into endothelial cells, providing a cellular model investigating anti‑angiogenic mechanisms in vitro. The breast cancer cell line MCF‑7 was used, and the expression of CD133 was initially detected using flow cytometry. CD133⁺ breast cancer cells were purified using immunomagnetic bead sorting technology, yielding an MCF‑7^CD133+ subpopulation. The proliferation ability of these cells was assessed using an MTT assay, while their microsphere formation ability was evaluated using a microsphere formation assay. Post‑transformation in an optimized endothelial cell culture medium, expression of endothelial cell markers CD31 and CD105 were detected using flow cytometry. Endothelial cell tube formation assays and DiI‑labeled acetylated low‑density lipoprotein (DiI‑Ac‑LDL) assays were employed to analyze the endothelial cell function of the MCF‑7^CD133+ cells. MDM2/CEN12 gene amplification was detected through fluorescence in situ hybridization (FISH). The MCF‑7 breast cancer cell line exhibited 1.7±0.3% trace cells expressing the stem cell surface marker CD133. After anti‑CD133 immunomagnetic bead sorting, MCF‑7^CD133+ and MCF‑7^CD133‑ subpopulation cells were obtained, with CD133 expression rates of 85.6±2.8 and 0.18±0.08%, respectively. MTT assay results demonstrated that, after 7 days, the proliferation rate of MCF‑7^CD133+ cells was significantly higher compared with MCF‑7^CD133‑ cells. MCF‑7^CD133+ subpopulation cells displayed strong stem cell characteristics, growing in suspension in serum‑free media and forming tumor cell spheres. In contrast, MCF‑7^CD133‑ cells failed to form microspheres. After culturing cells in endothelial cell differentiation and maintenance media, the percentage of MCF‑7^CD133+ cells before and after endothelial cell culture was 0.3±0.16 and 81.4±8.37% for CD31⁺ cells and 0.2±0.08 and 83.8±7.24% for CD105⁺ cells, respectively. Vascular‑like structure formation and Ac‑LDL phagocytosis with red fluorescence in the tube formation assays confirmed endothelial cell function in the MCF‑7^CD133+ cells. FISH was used to verify MDM2/CEN12 gene amplification in the induced MCF‑7^CD133+ cells, indicating tumor cell characteristics. The modified endothelial cell transformation medium effectively induced differentiated tumor stem cells to express vascular endothelial cell markers and exhibit endothelial functions, ideal for in vitro anti‑angiogenesis research.

View Figures

View References

1	Arnold M, Morgan E, Rumgay H, Mafra A, Singh D, Laversanne M, Vignat J, Gralow JR, Cardoso F, Siesling S and Soerjomataram I: Current and future burden of breast cancer: Global statistics for 2020 and 2040. Breast. 66:15–23. 2022.PubMed/NCBI View Article : Google Scholar
2	Rivenbark AG, O'Connor SM and Coleman WB: Molecular and cellular heterogeneity in breast cancer. Am J Pathol. 183:1113–1124. 2013.PubMed/NCBI View Article : Google Scholar
3	Szczepanek J, Skorupa M, Jarkiewicz-Tretyn J, Cybulski C and Tretyn A: Harnessing epigenetics for breast cancer therapy: The role of DNA methylation, histone modifications, and microRNA. Int J Mol Sci. 24(7235)2023.PubMed/NCBI View Article : Google Scholar
4	Mackillop WJ, Ciampi A, Till JE and Buick RN: A stem cell model of human tumor growth: implications for tumor cell clonogenic assays. J Natl Cancer Inst. 70:9–16. 1983.PubMed/NCBI
5	Llaguno SA and Parada LF: Cancer stem cells in gliomas: Evolving concepts and therapeutic implications. Curr Opin Neurol. 34:868–874. 2021.PubMed/NCBI View Article : Google Scholar
6	Diehn M, Cho RW, Lobo NA, Kalisky T, Dorie MJ, Kulp AN, Qian D, Lam JS, Ailles LE, Wong MZ, et al: Association of reactive oxygen species levels and radioresistance in cancer stem cells. Nature. 458:780–783. 2009.PubMed/NCBI View Article : Google Scholar
7	Hu Y and Fu L: Targeting cancer stem cells: A new therapy to cure cancer patients. Am J Cancer Res. 2:340–356. 2012.PubMed/NCBI
8	Loureiro R, Mesquita KA, Oliveira PJ and Vega-Naredo I: Mitochondria in cancer stem cells: A target for therapy. Recent Pat Endocr Metab Immune Drug Discov. 7:102–114. 2013.PubMed/NCBI View Article : Google Scholar
9	Phi LH, Sari IN, Yang YG, Lee SH, Jun NY, Kim KS, Lee YK and Kwon HY: Cancer stem cells (CSCs) in drug resistance and their therapeutic implications in cancer treatment. Stem Cells Int. 28(5416923)2018.PubMed/NCBI View Article : Google Scholar
10	Griguer CE, Oliva CR, Gobin E, Marcorelles P, Benos DJ, Lancaster JR and Gillespie GY: CD133 is a marker of bioenergetic stress in human glioma. PLoS One. 3(e3655)2008.PubMed/NCBI View Article : Google Scholar
11	Kunihiro AG, Sarrett SM, Lastwika KJ, Solan JL, Pisarenko T, Keinänen O, Rodriguez O, Taverne LR, Fitzpatrick AL, Li CI, et al: CD133 as a biomarker for an autoantibody-to-immunoPET paradigm for the early detection of small cell lung cancer. J Nucl Med. 63:1701–1707. 2022.PubMed/NCBI View Article : Google Scholar
12	Howard R, Diffalha SA, Pimiento J, Mejia J, Enderling H, Giuliano A and Coppola D: CD133 expression as a helicobacter pylori-independent biomarker of gastric cancer progression. Anticancer Res. 38:4443–4448. 2018.PubMed/NCBI View Article : Google Scholar
13	Ikram D, Masadah R, Nelwan BJ, Zainuddin AA, Ghaznawie M and Wahid S: CD133 act as an essential marker in ovarian carcinogenesis. Asian Pac J Cancer Prev. 22:3525–3531. 2021.PubMed/NCBI View Article : Google Scholar
14	Lugano R, Ramachandran M and Dimberg A: Tumor angiogenesis: Causes, consequences, challenges and opportunities. Cell Mol Life Sci. 77:1745–1770. 2020.PubMed/NCBI View Article : Google Scholar
15	Liu ZL, Chen HH, Zheng LL, Sun LP and Shi L: Angiogenic signaling pathways and anti-angiogenic therapy for cancer. Signal Transduct Target Ther. 8(198)2023.PubMed/NCBI View Article : Google Scholar
16	Viallard C and Larrivée B: Tumor angiogenesis and vascular normalization: alternative therapeutic targets. Angiogenesis. 20:409–426. 2017.PubMed/NCBI View Article : Google Scholar
17	Ferrara N, Gerber HP and LeCouter J: The biology of VEGF and its receptors. Nat Med. 9:669–676. 2003.PubMed/NCBI View Article : Google Scholar
18	Apte RS, Chen DS and Ferrara N: VEGF in signaling and disease: Beyond discovery and development. Cell. 176:1248–1264. 2019.PubMed/NCBI View Article : Google Scholar
19	Turner N and Grose R: Fibroblast growth factor signaling: from development to cancer. Nat Rev Cancer. 10:116–129. 2010.PubMed/NCBI View Article : Google Scholar
20	Johnson KE and Wilgus TA: Vascular endothelial growth factor and angiogenesis in the regulation of cutaneous wound repair. Adv Wound Care (New Rochelle). 3:647–661. 2014.PubMed/NCBI View Article : Google Scholar
21	Phillips TM, McBride WH and Pajonk F: The response of CD24(-/low)/CD44+ breast cancer-initiating cells to radiation. J Natl Cancer Inst. 98:1777–1785. 2006.PubMed/NCBI View Article : Google Scholar
22	Puca F, Fedele M, Rasio D and Battista S: Role of diet in stem and cancer stem cells. Int J Mol Sci. 23(8108)2022.PubMed/NCBI View Article : Google Scholar
23	Katayama Y, Uchino J, Chihara Y, Tamiya N, Kaneko Y, Yamada T and Takayama K: Tumor neovascularization and developments in therapeutics. Cancers (Basel). 11(316)2019.PubMed/NCBI View Article : Google Scholar
24	Aomatsu N, Yashiro M, Kashiwagi S, Takashima T, Ishikawa T, Ohsawa M, Wakasa K and Hirakawa K: CD133 is a useful surrogate marker for predicting chemosensitivity to neoadjuvant chemotherapy in breast cancer. PLoS One. 7(e45865)2012.PubMed/NCBI View Article : Google Scholar
25	Sun C, Li JM, Wang B, Shangguan JJ, Figini M, Shang N, Pan L and Zhang ZL: Tumor angiogenesis and bone metastasis-correlation in invasive breast carcinoma. J Immunol Methods. 452:46–52. 2018.PubMed/NCBI View Article : Google Scholar
26	Lv XQ, Wang YZ, Song YM, Pang X and Li HX: Association between ALDH1⁺/CD133⁺ stem-like cells and tumor angiogenesis in invasive ductal breast carcinoma. Oncol Lett. 11:1750–1756. 2016.PubMed/NCBI View Article : Google Scholar
27	Sudhan DR, Rabaglino MB, Wood CE and Siemann DW: Cathepsin L in tumor angiogenesis and its therapeutic intervention by the small molecule inhibitor KGP94. Clin Exp Metastasis. 33:461–73. 2016.PubMed/NCBI View Article : Google Scholar
28	Kim W, Kim KS and Park RW: Nomogram of naive bayesian model for recurrence prediction of breast cancer. Healthc Inform Res. 22:89–94. 2016.PubMed/NCBI View Article : Google Scholar
29	Panigoro SS, Kurnia D, Kurnia A, Haryono SJ and Albar ZA: ALDH1 cancer stem cell marker as a prognostic factor in triple-negative breast cancer. Int J Surg Oncol. 2020(7863243)2020.PubMed/NCBI View Article : Google Scholar
30	Yu JG, Liao XH, Li YL, Lv L, Zhi XL, Yu J and Zhou P: A preliminary study of the role of extracellular-5'-nucleotidase in breast cancer stem cells and epithelial-mesenchymal transition. In Vitro Cell Dev Biol Anim. 53:132–140. 2017.PubMed/NCBI View Article : Google Scholar
31	Yang LQ, Shi PF and Zhao GC: Targeting cancer stem cell pathways for cancer therapy. Signal Transduct Target Ther. 5(8)2020.PubMed/NCBI View Article : Google Scholar
32	Irollo E and Pirozzi G: CD133: To be or not to be, is this the real question? Am J Transl Res. 5:563–581. 2013.PubMed/NCBI
33	Bauer N, Fonseca AV, Florek M, Freund D, Jászai J, Bornhäuser M, Fargeas CA and Corbeil D: New insights into the cell biology of hematopoietic progenitors by studying prominin-1 (CD133). Cells Tissues Organs. 188:127–138. 2008.PubMed/NCBI View Article : Google Scholar
34	Zou L, Liu XW, Li JJ, Li W, Zhang LL, Li J and Zhang JM: Tetramethylpyrazine enhances the antitumor effect of paclitaxel by inhibiting angiogenesis and inducing apoptosis. Front Pharmacol. 10(707)2019.PubMed/NCBI View Article : Google Scholar
35	Ahmed N, Abubaker K, Findlay J and Quinn M: Epithelial mesenchymal transition and cancer stem cell-like phenotypes facilitate chemoresistance in recurrent ovarian cancer. Curr Cancer Drug Targets. 10:268–278. 2010.PubMed/NCBI View Article : Google Scholar
36	Liu XM, Zhang QP, Mu YG, Zhang XH, Sai K, Pang JC, Ng HK and Chen ZP: Clinical significance of vasculogenic mimicry in human gliomas. J Neurooncol. 105:173–179. 2011.PubMed/NCBI View Article : Google Scholar
37	Alvero AB, Chen R, Fu HH, Montagna M, Schwart PE, Rutherford T, Silasi DA, Steffensen KD, Waldstrom M, Visintin I and Mor G: Molecular phenotyping of human ovarian cancer stem cells unravels the mechanisms for repair and chemoresistance. Cell Cycle. 8:158–166. 2009.PubMed/NCBI View Article : Google Scholar
38	Yuan Y, Jiang YC, Sun CK and Chen QM: Role of the tumor microenvironment in tumor progression and the clinical applications (review). Oncol Rep. 35:2499–2515. 2016.PubMed/NCBI View Article : Google Scholar
39	Hinshaw DC and Shevde LA: The tumor microenvironment innately modulates cancer progression. Cancer Res. 79:4557–4566. 2019.PubMed/NCBI View Article : Google Scholar
40	Rohlenova K, Veys K, Miranda-Santos I, Bock KD and Carmeliet P: Endothelial cell metabolism in health and disease. Trends Cell Biol. 28:224–236. 2018.PubMed/NCBI View Article : Google Scholar
41	Muz B, Puente PD, Azab F and Azab AK: The role of hypoxia in cancer progression, angiogenesis, metastasis, and resistance to therapy. Hypoxia (Auckl). 3:83–92. 2015.PubMed/NCBI View Article : Google Scholar
42	Vasudev NS and Reynolds AR: Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions. Angiogenesis. 17:471–494. 2014.PubMed/NCBI View Article : Google Scholar
43	Alexandre J, Batteux F, Nicco C, Chéreau C, Laurent A, Guillevin L, Weill B and Goldwasser F: . Accumulation of hydrogen peroxide is an early and crucial step for paclitaxel-induced cancer cell death both in vitro and in vivo. Int J Cancer. 119:41–48. 2006.PubMed/NCBI View Article : Google Scholar
44	Fukui M, Yamabe N and Zhu BT: . Resveratrol attenuates the anticancer efficacy of paclitaxel in human breast cancer cells in vitro and in vivo. Eur J Cancer. 46:1882–1891. 2010.PubMed/NCBI View Article : Google Scholar
45	Haibe Y, Kreidieh M, El Hajj H, Khalifeh I, Mukherji D, Temraz S and Shamseddine A: Resistance mechanisms to anti-angiogenic therapies in cancer. Front Oncol. 10(221)2020.PubMed/NCBI View Article : Google Scholar
46	Ansari MJ, Bokov D, Markov A, Jalil AT, Shalaby MN, Suksatan W, Chupradit S, Al-Ghamdi HS, Shomali N, Zamani A, et al: Cancer combination therapies by angiogenesis inhibitors; a comprehensive review. Cell Commun Signal. 20(49)2022.PubMed/NCBI View Article : Google Scholar
47	Eelen G, Treps L, Li XR and Carmeliet P: Basic and therapeutic aspects of angiogenesis updated. Circ Res. 127:310–329. 2020.PubMed/NCBI View Article : Google Scholar
48	Lee WS, Yang H, Chon HJ and Kim C: Combination of anti-angiogenic therapy and immune checkpoint blockade normalizes vascular-immune crosstalk to potentiate cancer immunity. Exp Mol Med. 52:1475–1485. 2020.PubMed/NCBI View Article : Google Scholar
49	Huinen ZR, Huijbers EJ, Beijnum JR, Nowak-Sliwinska P and Griffioen AW: Anti-angiogenic agents-overcoming tumour endothelial cell anergy and improving immunotherapy outcomes. Nat Rev Clin Oncol. 18:527–540. 2021.PubMed/NCBI View Article : Google Scholar
50	Wehland M, Bauer J, Infanger M and Grimm M: Target-based anti-angiogenic therapy in breast cancer. Curr Pharm Des. 18:4244–4257. 2012.PubMed/NCBI View Article : Google Scholar
51	Yetkin-Arik B, Kastelein AW, Klaassen I, Jansen CH, Latul YP, Vittori M, Biri A, Kahraman K, Griffioen AW, Amant F, et al: Angiogenesis in gynecological cancers and the options for anti-angiogenesis therapy. Biochim Biophys Acta Rev Cancer. 1875(188446)2021.PubMed/NCBI View Article : Google Scholar
52	Fukumura D and Jain RK: Tumor microvasculature and microenvironment: targets for anti-angiogenesis and normalization. Microvasc Res. 74:72–84. 2007.PubMed/NCBI View Article : Google Scholar